EU Novel Food Rules Wipe French CBD Gummies

1997 Cutoff Date Defines Legal CBD Fate

The core of the issue lies in the definition of "novel food," a legal term that determines what can be eaten in Europe.

Under EU law, any food that was not "used for human consumption to a significant degree" within the Union before 15 May 1997 requires a safety assessment and authorisation before it can be marketed.

While hemp seeds and hemp oil have a history of consumption stretching back centuries, the European Commission maintains that CBD extracts and isolates do not.

This distinction is crucial for the millions of Europeans who have incorporated CBD into their daily routines.

The Commission argues that the extraction processes used to isolate CBD from the cannabis plant are modern technological innovations.

Therefore, the resulting chemical compound is considered a novel food.

This interpretation was solidified in a 2020 guidance document that sent shockwaves through the industry.

"The extraction of CBD constitutes a significant change in the production process," officials stated in the guidance.

Consequently, manufacturers cannot simply rely on the history of the hemp plant to prove safety.

They must prove that their specific extraction method and the final chemical composition are safe for human consumption.

This requirement has created a bottleneck.

Large multinational companies have the resources to fund the necessary toxicological studies, but smaller French artisans do not.

The regulation applies to all forms of CBD intended for ingestion, including oils, capsules, and the now-banned gummies.

However, gummies have been the primary target of the August 2026 enforcement due to their popularity among younger demographics and the ease with which they can be overdosed compared to tinctures.

• EU Novel Food cutoff date is 15 May 1997.
• CBD extracts are considered new production methods, not traditional foods.
• Safety assessments are mandatory for all ingestion methods.

The historical context is lost on many consumers who view CBD as a natural wellness supplement.

Yet, from a regulatory standpoint, the white powder or golden oil added to gummy bears bears little resemblance to the rough hemp seeds consumed in the 20th century.

This regulatory gap has finally closed, leaving the industry to play catch-up with science and bureaucracy.

EFSA Demands Toxicology Data for Edibles

The European Food Safety Authority (EFSA), the EU's scientific risk assessment body, has repeatedly highlighted data gaps regarding the safety of CBD.

In June 2022, EFSA suspended its evaluation of CBD novel food applications because industry data failed to address safety concerns.

Specifically, regulators are worried about the potential effects of CBD on the liver, the reproductive system, and the human endocrine system.

Animal studies have shown links between high doses of CBD and liver toxicity.

While human studies are limited, the precautionary principle dictates that regulators must err on the side of caution.

For a product like a gummy, which is often consumed as a sweet treat rather than a supplement, the risk of accidental high intake is significant.

"The available data on the safety of CBD is not sufficient to determine a safe level of daily intake," experts noted in the 2022 assessment.

This lack of a "safety threshold" is the primary reason why gummies have been pulled from French shelves today.

Without a defined limit, regulators cannot set a maximum permitted dosage for the product.

Consequently, the sale of such products is prohibited until manufacturers can provide comprehensive dossiers proving they are safe.

These dossiers must include data on genotoxicity, sub-chronic toxicity, and chronic toxicity.

The cost of generating this data runs into the hundreds of thousands of euros.

For many French CBD startups, this cost is prohibitive.

The situation creates a paradox.

Millions of Europeans have used CBD products for years without reported widespread epidemics of liver failure.

Yet, the absence of formal clinical data means the products remain technically illegal under EU food law.

• EFSA suspended evaluation in June 2022 due to data gaps.
• Animal studies indicate potential liver toxicity at high doses.
• No safe daily intake level has been established for CBD.

This scientific stalemate has left the French market in limbo.

While the French government has generally been supportive of the hemp industry, it cannot unilaterally override EU food safety regulations.

French officials have urged the industry to cooperate with EFSA and submit the required data.

However, the process is slow.

Even if a company submits a perfect dossier tomorrow, the evaluation process could take another 18 to 24 months.

This timeline suggests that French consumers should not expect the legal return of CBD gummies anytime soon.

French Courts Draw Line on THC Limits

While the Novel Food regulations address the safety of the CBD molecule itself, French law has also been grappling with the presence of THC, the psychoactive compound in cannabis.

France has historically maintained one of the strictest THC limits in Europe.

For years, the government enforced a zero-tolerance policy for THC in hemp-derived products, effectively banning the sale of CBD flowers.

This stance was challenged in court and eventually overturned.

In January 2023, the French Council of State ruled that the zero-tolerance rule was illegal, bringing France into line with EU standards allowing a THC limit of 0.3%.

However, this legal victory for the CBD industry has been overshadowed by the Novel Food enforcement.

Even if a gummy contains less than 0.3% THC, it is still subject to the Novel Food requirement because it contains CBD extract.

"The THC limit is a separate issue from the Novel Food classification," legal experts clarified.

"You can pass the THC test but fail the Novel Food test."

This dual layer of regulation has created a complex compliance puzzle for manufacturers.

They must ensure their raw materials contain less than 0.3% THC to avoid prosecution as narcotics.

Simultaneously, they must secure Novel Food authorisation to avoid prosecution for selling unsafe food.

Currently, almost no CBD gummy on the market meets both criteria.

The result is a de facto ban.

French authorities have indicated that they will prioritise the Novel Food aspect in their inspections throughout 2026.

The logic is that the Novel Food rules cover the broader safety of the product, including the effects of the CBD itself.

• French courts overturned zero-tolerance THC rules in January 2023.
• EU legal THC limit for hemp is 0.3%.
• Novel Food rules apply regardless of THC content.

The legal landscape in France remains volatile.

While the Council of State opened the door for CBD flowers, the European Commission has closed the window for edibles.

This inconsistency frustrates industry leaders who argue that if smoking CBD flower is legal, eating a gummy should be too.

However, regulators counter that smoking is not a food consumption method and therefore falls outside the scope of the Novel Food regulation.

This technicality has preserved the market for raw flower while decimating the market for processed edibles.

Compliance Costs Force Small Firms to Exit

The economic impact of the Novel Food enforcement is being felt acutely by France's small and medium-sized enterprises (SMEs).

The CBD boom in France was largely driven by grassroots entrepreneurs who opened vape shops and wellness boutiques.

These businesses lack the financial muscle of pharmaceutical giants.

To obtain a Novel Food authorisation, a company must compile a dossier containing extensive scientific studies.

This includes stability tests, heavy metal analysis, pesticide residue testing, and toxic